Insulet (PODD) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Insulet Corporation  (NASDAQ: PODD)

Insulet's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Insulet in the second quarter 2026?
Insulet Corporation achieved a return on average equity (ROE) of 26.69 % in its second quarter 2026, this is above PODD's average return on equity of -24.5%.
Insulet Corporation shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $1,406 million

ROE has advanced compared to 21.38% in the first quarter 2026, due to net income growth.

Within the Medical Equipment & Supplies industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 528 to 617.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -2.78 % -2.11 % 25.06 % 23.8 % -
Y / Y Net Income Change 322.22 % 157.34 % 0.89 % 13.03 % -88.07 %
Net Income (TTM) in Millions 375 303 247 246 236
Return On Equity (TTM) 26.69 % 21.38 % 17.36 % 18.27 % 18.43 %
PODD's Total Ranking # 617 # 528 # 599 # 637 # 586
Equity (TTM) in Millions 1,422 1,303 1,515 1,384 1,463
Seq. Equity Change 9.18 % -14.03 % 9.47 % -5.39 % 9.93 %
Seq. Net Income Change 4.28 % -10.33 % 15.98 % 289.33 % -36.44 %

Back to PODD Management Effectiveness >> PODD's 5 Years Annual ROE >> Compare PODD ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 10
Sector # 61
Overall # 617

Return On Equity Statistics
High Average Low
50.53 %
-24.5 %
-176.01 %
(Jun 30 2024)   (Jun 30 2016)



  News about Insulet Corporation Return on Equity ROE

Insulet Corporation Achieves Key FDA Clearance and Opens New Malaysian Facility Amid Strong Financial Growth,...

Insulet Corporation (NASDAQ: PODD), a pioneer in tubeless insulin pump technology, has reached significant milestones that enhance its position in the diabetes management industry. The recent U.S. Food and Drug Administration (FDA) clearance for Insulet’s Omnipod 5 Automated Insulin Delivery (AID) System for use in adults with type 2 diabetes, together with the opening of a new manufacturing facility in Johor Bahru, Malaysia, marks a notable expansion of the company s capabilities and market footprint.The Omnipod 5 AID System, now approved for both type 1 and type 2 diabetes, represents a landmark in diabetes care. It stands as the first and only tubeless automated insulin delivery system approved by the FDA for this broader patient demographic. This development provides an innovative alternative for the 34 million Americans living with diabetes, many of whom require diligent and precise insulin management. Jim Hollingshead, President and Chief Executive Officer of Insulet, emphasized the transformative impact of the Omnipod 5 on diabetes management. He noted, With this approval, we are able to extend the benefits of our advanced insulin delivery system to a larger population, providing more options and better health outcomes.



PODD Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 1,515 1,212 733 476 556
Y / Y Equity Change 25.06 % 65.36 % 53.8 % -14.36 % -7.84 %
Net Income in Millions 247 418 206 5 17
Y / Y Net Income Change -40.93 % 102.76 % 4384.78 % -72.62 % 147.06 %
Return On Equity 16.31 % 34.52 % 28.16 % 0.97 % 3.02 %

Back to PODD Management Effectiveness >> PODD's 5 Years Annual ROE >> Compare PODD ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 16.31 %, due to deterioration of net income.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PODD's' Return on Equity at Yahoo Finance
PODD's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PODD's Competitors
Subscribers only: Roe for Insulet's Suppliers
Subscribers only: Return On Equity for PODD's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %

Date modified: 2026-09-11T09:47:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.